Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Acumen Pharmaceuticals Inc
(NQ:
ABOS
)
2.350
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1
Open
2.350
Bid (Size)
2.100 (10)
Ask (Size)
2.640 (1)
Prev. Close
2.350
Today's Range
2.350 - 2.350
52wk Range
1.810 - 5.090
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
September 30, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
September 26, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
-44.44%
-44.44%
1 Month
-7.48%
-7.48%
3 Month
-18.83%
-18.83%
6 Month
-33.43%
-33.43%
1 Year
-37.33%
-37.33%
More News
Read More
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
September 25, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals's Earnings: A Preview
March 25, 2024
Via
Benzinga
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
September 03, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024
August 13, 2024
Via
InvestorPlace
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
August 06, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
July 29, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 28, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 11, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Trading SMID Biotech Stocks In A Volatile Market
July 01, 2024
Via
Talk Markets
ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 14, 2024
Via
Benzinga
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
May 08, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
May 07, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
April 16, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
April 04, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
March 26, 2024
Via
InvestorPlace
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
March 26, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
March 21, 2024
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 26, 2024
March 26, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.